S. 2510 · 118th Congress (2023–2025)
RAPID Reserve Act
This bill requires the Department of Health and Human Services to contract with drug manufacturers to ensure adequate supplies of critical drugs that have vulnerable supply chains. (Under the bill, drugs are considered critical if they are likely to be needed during a public health emergency or if a shortage would pose a significant threat to the health care system or at-risk populations.)
Contracted drug manufacturers must agree to (1) maintain at least a 6-month reserve of the active ingredient in a critical drug and of the finished product and to regularly replenish these reserves, (2) produce the ingredient and drug in a manner and quantity as specified in the contract, and (3) agree to transfer portions of the reserve, if necessary, to other manufacturers to meet manufacturing needs and allow HHS to control the allocation of reserves in the event of a public health emergency or other threat.
HHS must publish a list of critical drugs and issue guidance on the criteria for determining this list and awarding contracts. HHS must give preference to domestic manufacturers for contracts.
In addition, the Government Accountability Office must report on the capacity of domestic manufacturing with respect to critical drugs, including the ability to manufacture different dosage forms and drugs with various characteristics.
Show official title
A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 2510’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Gary C. Peters (D-MI)
- Cosponsors
5 cosponsors
2 original · 3 later
- Sen. Sherrod Brown (D-OH)· Original · Jul 26, 2023
- Sen. Marsha Blackburn (R-TN)· Original · Jul 26, 2023
- Sen. Ted Budd (R-NC)· Later · Oct 4, 2023
- Sen. Joni Ernst (R-IA)· Later · Oct 19, 2023
- Sen. Peter Welch (D-VT)· Later · Oct 19, 2023
- Policy area
- Health
- Subjects
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Government studies and investigations
- Manufacturing
- Prescription drugs
- Public contracts and procurement
- Strategic materials and reserves
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (3)
RAPID Reserve Act
Display title, Short title · Introduced in Senate
Rolling Active Pharmaceutical Ingredient and Drug Reserve Act
Short title · Introduced in Senate
A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.
Official title · Introduced in Senate